Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
Relmada Therapeutics Inc RLMD
$4.20
▲ +1.45%
(+$0.06)
📅 Earnings This Week
Open
$4.11
Prev Close
$4.14
Day Range
$4.11 – $4.26
52W Range
$2.42 – $8.00
Market Cap
$441.61M
Beta
0.50
EPS (TTM)
$-0.96
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-03-03 |
| Shares Out. | 106,670,000 |
| Website | relmada.com/ ↗ |
| Phone | 17866291376 |
| Employees | 17 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$12.9M |
| Free Cash Flow | -$46.0M |
| Total Assets | $219.1M |
| Total Liabilities | $12.5M |
| Equity | $206.6M |
About Relmada Therapeutics Inc
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Relmada Therapeutics Inc is a publicly traded company under the ticker symbol RLMD on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-11-01)